Aegerion Pharmaceuticals Inc. (NYSE: AEGR) expects a potential of up to $1 billion in global sales of its recently approved Juxtapid. Shares of the biopharmaceutical jumped $14.73 to close at $61.70.
Aegerion Expects $1 Billion In Sales
May 16, 2013 at 19:23 PM EDT
